CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of cancer
3.4.1.2. Increase in demand for ideal therapeutics for treatment
3.4.1.3. Rise in adoption of Artificial Intelligence (AI) based diagnosis
3.4.2. Restraints
3.4.2.1. High cost of personalized medicine
3.4.2.2. Limited Reimbursement and coverage
3.4.3. Opportunities
3.4.3.1. Increase in R&D activities in personalized cancer medicine
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Personalized Medicine Therapeutics
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Personalized Medicine Diagnostics
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: PERSONALIZED CANCER MEDICINE MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals and clinics
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Others
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: PERSONALIZED CANCER MEDICINE MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Product
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Product
6.2.4.1.3. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Product
6.2.4.2.3. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Product
6.2.4.3.3. Market size and forecast, by End User
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Product
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Product
6.3.4.1.3. Market size and forecast, by End User
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Product
6.3.4.2.3. Market size and forecast, by End User
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Product
6.3.4.3.3. Market size and forecast, by End User
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Product
6.3.4.4.3. Market size and forecast, by End User
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Product
6.3.4.5.3. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Product
6.3.4.6.3. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Product
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Product
6.4.4.1.3. Market size and forecast, by End User
6.4.4.2. China
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Product
6.4.4.2.3. Market size and forecast, by End User
6.4.4.3. Australia
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Product
6.4.4.3.3. Market size and forecast, by End User
6.4.4.4. Rest of Asia-Pacific
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Product
6.4.4.4.3. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Product
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Latin America
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Product
6.5.4.1.3. Market size and forecast, by End User
6.5.4.2. Middle East And Africa
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Product
6.5.4.2.3. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. ARIEL Precision Medicine, Inc.
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.3. F. Hoffmann-La Roche Ltd.
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. General Electric
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Aadi Bioscience, Inc.
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Illumina, Inc.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Qiagen NV.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. Thermo Fisher Scientific Inc.
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. Bristol-Myers Squibb Company
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
TABLE 01. GLOBAL PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 02. PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY REGION, 2022-2032 ($BILLION)
TABLE 03. PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY REGION, 2022-2032 ($BILLION)
TABLE 04. GLOBAL PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 05. PERSONALIZED CANCER MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($BILLION)
TABLE 06. PERSONALIZED CANCER MEDICINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($BILLION)
TABLE 07. PERSONALIZED CANCER MEDICINE MARKET, BY REGION, 2022-2032 ($BILLION)
TABLE 08. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 09. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 10. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 11. U.S. PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 12. U.S. PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 13. CANADA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 14. CANADA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 15. MEXICO PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 16. MEXICO PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 17. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 18. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 19. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 20. GERMANY PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 21. GERMANY PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 22. FRANCE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 23. FRANCE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 24. UK PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 25. UK PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 26. ITALY PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 27. ITALY PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 28. SPAIN PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 29. SPAIN PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 30. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 31. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 32. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 33. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 34. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 35. JAPAN PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 36. JAPAN PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 37. CHINA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 38. CHINA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 39. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 40. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 41. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 42. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 43. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 44. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 45. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 46. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 47. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 48. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
TABLE 49. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
TABLE 50. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 51. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 52. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 53. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 54. ARIEL PRECISION MEDICINE, INC.: KEY EXECUTIVES
TABLE 55. ARIEL PRECISION MEDICINE, INC.: COMPANY SNAPSHOT
TABLE 56. ARIEL PRECISION MEDICINE, INC.: PRODUCT SEGMENTS
TABLE 57. ARIEL PRECISION MEDICINE, INC.: PRODUCT PORTFOLIO
TABLE 58. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 59. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 60. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 61. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 62. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 63. GENERAL ELECTRIC: KEY EXECUTIVES
TABLE 64. GENERAL ELECTRIC: COMPANY SNAPSHOT
TABLE 65. GENERAL ELECTRIC: SERVICE SEGMENTS
TABLE 66. GENERAL ELECTRIC: PRODUCT PORTFOLIO
TABLE 67. GENERAL ELECTRIC: KEY STRATERGIES
TABLE 68. AADI BIOSCIENCE, INC.: KEY EXECUTIVES
TABLE 69. AADI BIOSCIENCE, INC.: COMPANY SNAPSHOT
TABLE 70. AADI BIOSCIENCE, INC.: PRODUCT SEGMENTS
TABLE 71. AADI BIOSCIENCE, INC.: PRODUCT PORTFOLIO
TABLE 72. AADI BIOSCIENCE, INC.: KEY STRATERGIES
TABLE 73. ILLUMINA, INC.: KEY EXECUTIVES
TABLE 74. ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 75. ILLUMINA, INC.: PRODUCT SEGMENTS
TABLE 76. ILLUMINA, INC.: PRODUCT PORTFOLIO
TABLE 77. ILLUMINA, INC.: KEY STRATERGIES
TABLE 78. QIAGEN NV.: KEY EXECUTIVES
TABLE 79. QIAGEN NV.: COMPANY SNAPSHOT
TABLE 80. QIAGEN NV.: PRODUCT SEGMENTS
TABLE 81. QIAGEN NV.: PRODUCT PORTFOLIO
TABLE 82. QIAGEN NV.: KEY STRATERGIES
TABLE 83. NOVARTIS AG: KEY EXECUTIVES
TABLE 84. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 85. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 86. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 87. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 88. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 89. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 90. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 91. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 92. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 93. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 94. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
